14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:EBIO
Delisted

Eleven Biotherapeutics Fund Signals

$3.29
+0 (+0%)
At Close: May 31, 2018

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 3.130 33 days ( -108.23 % )
Last Price $3.29 0 %
High/ Low $3.29 - $3.29 0%
Chg 7 Days N/A $3.29 $3.29
Chg 30 Days 13.06 % $2.91 $3.29
Chg 12 mos 140.15 % $1.37 $3.29
Trend - 3 mos 216.77 % Width: 44.32 %
Trend - 12 mos 24.51 % Width: 381.82 %
Pred. range - 3 mos $9.18 - $13.24 178.93 % - 302.56 %
Pred. range - 12 mos $0.86 - $4.16 -73.77 % - 26.40 %
Short MA avg 3 mos Buy May 15, 2018 - 12 days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Buy May 15, 2018 - 12 days
Long MA avg 12 mos Buy Feb 20, 2018 - 71 days
Short/Long MA avg 12 mos Buy Feb 26, 2018 - 67 days
Pivot Short Sell May 30, 2018 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The compa... EBIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT